GSK unit wins partial dismissal in dostarlimab licence dispute with AnaptysBio [Yahoo! Finance]
AnaptysBio, Inc. (ANAB)
Last anaptysbio, inc. earnings: 3/2 08:45 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.anaptysbio.com/investor-relations
Company Research
Source: Yahoo! Finance
GSK PLC's (LSE:GSK, NYSE:GSK) oncology subsidiary TESARO has secured a partial legal victory after a Delaware court dismissed a counterclaim brought by AnaptysBio, the US biotechnology company, in a dispute over the licence for cancer drug dostarlimab. The Delaware Chancery Court granted TESARO's motion to dismiss AnaptysBio's claim for anticipatory breach, though the ruling does not address the core contractual dispute between the parties. TESARO's remaining claim for declaratory judgment, which seeks a formal court ruling on the parties' legal rights under the licence agreement, is unaffected and will proceed to trial. The litigation stems from allegations by AnaptysBio that TESARO failed to fulfil certain requirements under a licence agreement signed in March 2014, with AnaptysBio threatening to revoke TESARO's licence for the drug. GSK and TESARO have rejected those allegations as entirely without merit. Dostarlimab, sold under the brand name Jemperli, is approved in mo
Show less
Read more
Impact Snapshot
Event Time:
ANAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANAB alerts
High impacting AnaptysBio, Inc. news events
Weekly update
A roundup of the hottest topics
ANAB
News
- AnaptysBio (ANAB) was given a new $85.00 price target by Leerink Partners.MarketBeat
- Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro’s Anticipatory Breach ClaimGlobeNewswire
- AnaptysBio (ANAB) had its price target lowered by Barclays PLC from $79.00 to $63.00. They now have an "overweight" rating on the stock.MarketBeat
- AnaptysBio: 'Hold' As Spin-Off Shifts Pipeline To First Tracks Biotherapeutics [Seeking Alpha]Seeking Alpha
- AnaptysBio (ANAB) was given a new $60.00 price target by UBS Group AG.MarketBeat
ANAB
Earnings
- 3/3/26 - Beat
ANAB
Sec Filings
- 4/24/26 - Form 8-K/A
- 4/23/26 - Form 4/A
- 4/22/26 - Form 4
- ANAB's page on the SEC website